|
1
|
Lee AW, Ng W, Chan Y, Sze H, Chan C and
Lam T: The battle against nasopharyngeal cancer. Radiother Oncol.
104:272–278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qu S, Liang ZG and Zhu XD: Advances and
challenges in intensity-modulated radiotherapy for nasopharyngeal
carcinoma. Asian Pac J Cancer Prev. 16:1687–1692. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hashim Nor NA, Ramzi NH, Velapasamy S,
Alex L, Chahil JK, Lye SH, Munretnam K, Haron MR and Ler LW:
Identification of genetic and non-genetic risk factors for
nasopharyngeal carcinoma in a southeast asian population. Asian Pac
J Cancer Prev. 13:6005–6010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li JX, Lu TX, Huang Y and Han F: Clinical
characteristics of recurrent nasopharyngeal carcinoma in
high-incidence area. ScientificWorldJournal. 2012:7197542012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chau RM, Teo PM, Kam MK, Leung S, Cheung K
and Chan AT: Dosimetric comparison between 2-dimensional radiation
therapy and intensity modulated radiation therapy in treatment of
advanced T-stage nasopharyngeal carcinoma: To treat less or more in
the planning organ-at-risk volume of the brainstem and spinal cord.
Med Dosim. 32:263–270. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen AM, Yang C, Marsano J, Liu T and
Purdy J: Intensity-modulated radiotherapy for nasopharyngeal
carcinoma: Improvement of the therapeutic ratio with helical
tomotherapy vs segmental multileaf collimator-based techniques. Br
J Radiol. 85:e537–e543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Du L, Zhang XX, Ma L, Feng LC, Li F, Zhou
GX, Qu BL, Xu SP, Xie CB and Yang J: Clinical study of
nasopharyngeal carcinoma treated by helical tomotherapy in China:
5-year outcomes. Biomed Res Int. 2014:9807672014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang FM, Chien CY, Tsai WL, Chen HC, Hsu
HC, Lui CC, Huang TL and Huang HY: Quality of life and survival
outcome for patients with nasopharyngeal carcinoma receiving
three-dimensional conformal radiotherapy vs. intensity-modulated
radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys.
72:356–364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He X, Ye M, Guo X, Pan Z, Zhang Z, He S
and Liu T: Treatment outcome of patients with stages I–II
nasopharyngeal carcinoma after late course accelerated
hyperfractionation radiotherapy alone. Oral Oncol. 48:1058–1063.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Belloni E, Trubia M, Gasparini P, Micucci
C, Tapinassi C, Confalonieri S, Nuciforo P, Martino B, Lo-Coco F,
Pelicci PG and Di Fiore PP: 8p11 myeloproliferative syndrome with a
novel t(7; 8) translocation leading to fusion of the FGFR1 and TIF1
genes. Genes Chromosomes Cancer. 42:320–325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong S, Delva L, Rachez C, Cenciarelli C,
Gandini D, Zhang H, Kalantry S, Freedman LP and Pandolfi PP: A
RA-dependent, tumour-growth suppressive transcription complex is
the target of the PML-RARα and T18 oncoproteins. Nat Genet.
23:287–295. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groner AC, Cato L, de Tribolet-Hardy J,
Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB,
Tschopp P, Gu L, et al: TRIM24 is an oncogenic transcriptional
activator in prostate cancer. Cancer Cell. 29:846–858. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chambon M, Orsetti B, Berthe ML,
Bascoul-Mollevi C, Rodriguez C, Duong V, Gleizes M, Thénot S,
Bibeau F, Theillet C and Cavaillès V: Prognostic significance of
TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol.
178:1461–1469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia
W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, et al: TRIM24
links a non-canonical histone signature to breast cancer. Nature.
468:927–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Allton K, Jain AK, Herz HM, Tsai WW, Jung
SY, Qin J, Bergmann A, Johnson RL and Barton MC: Trim24 targets
endogenous p53 for degradation. Proc Natl Acad Sci USA.
106:11612–11616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jain AK and Barton MC: Regulation of p53:
TRIM24 enters the RING. Cell Cycle. 8:3668–3674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang S, Minter LC, Stratton SA, Yang P,
Abbas HA, Akdemir ZC, Pant V, Post S, Gagea M, Lee RG, et al:
TRIM24 suppresses development of spontaneous hepatic lipid
accumulation and hepatocellular carcinoma in mice. J Hepatol.
62:371–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z, Luo
W, Qiu X and Wang E: Overexpression of TRIM24 correlates with tumor
progression in non-small cell lung cancer. PLoS One. 7:e376572012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Debatin KM: Apoptosis pathways in cancer
and cancer therapy. Cancer Immunol Immunother. 53:153–159. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stennicke HR and Salvesen GS: Biochemical
characteristics of caspases-3,-6,-7, and-8. J Biol Chem.
272:25719–25723. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lavrik IN, Golks A and Krammer PH:
Caspases: Pharmacological manipulation of cell death. J Clin
Invest. 115:2665–2672. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hong B, Lui VW, Hashiguchi M, Hui EP and
Chan AT: Targeting tumor hypoxia in nasopharyngeal carcinoma. Head
Neck. 35:133–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nyberg P, Salo T and Kalluri R: Tumor
microenvironment and angiogenesis. Front Biosci. 13:6537–6553.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bai Y, Zhu X, Chao J, Zhang Y, Qian C, Li
P, Liu D, Han B, Zhao L, Zhang J, et al: Pericytes contribute to
the disruption of the cerebral endothelial barrier via increasing
VEGF expression: Implications for stroke. PloS one.
10:e01243622015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Des Guetz G, Uzzan B, Nicolas P, Cucherat
M, Morere JF, Benamouzig R, Breau JL and Perret GY: Microvessel
density and VEGF expression are prognostic factors in colorectal
cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
30
|
Mullighan CG, Zhang J, Harvey RC,
Collins-Underwood JR, Schulman BA, Phillips LA, Tasian SK, Loh ML,
Su X, Liu W, et al: JAK mutations in high-risk childhood acute
lymphoblastic leukemia. Proc Natl Acad Sci USA. 106:9414–9418.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grandis JR, Drenning SD, Zeng Q, Watkins
SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y and Kim JD:
Constitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci.
97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du W, Hong J, Wang YC, Zhang YJ, Wang P,
Su WY, Lin YW, Lu R, Zou WP, Xiong H and Fang JY: Inhibition of
JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via
mitochondrial pathway. J Cell Mol Med. 16:1878–1888. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lv D, Li Y, Zhang W, Alvarez AA, Song L,
Tang J, Gao WQ, Hu B, Cheng SY and Feng H: TRIM24 is an oncogenic
transcriptional co-activator of STAT3 in glioblastoma. Nat Commun.
8:14542017. View Article : Google Scholar : PubMed/NCBI
|
